Lopinavir pharmacokinetics in COVID-19 patients - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Antimicrobial Chemotherapy Année : 2020

Lopinavir pharmacokinetics in COVID-19 patients

Résumé

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in late 2019. Therapeutic solutions are currently being tested for COVID-19, the SARS-CoV-2-associated pneumonia. Ritonavir-boosted lopinavir is included in the investigational therapies. A recent in vitro study reported that lopinavir inhibits SARS-CoV-2 replication with a 50% effective concentration (EC50) of 16 720 ng/mL.1 Here we describe lopinavir pharmacokinetics in COVID-19 patients treated with ritonavir-boosted lopinavir at the Nantes University Hospital, France.

Dates et versions

hal-03638958 , version 1 (12-04-2022)

Identifiants

Citer

Matthieu Grégoire, Paul Le Turnier, Benjamin Gaborit, Gwenaelle Veyrac, Raphaël Lecomte, et al.. Lopinavir pharmacokinetics in COVID-19 patients. Journal of Antimicrobial Chemotherapy, 2020, 75 (9), pp.2702-2704. ⟨10.1093/jac/dkaa195⟩. ⟨hal-03638958⟩
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More